Recently, KeyeLife Technology Co., Ltd. has achieved exciting progress in clinical trials of its self-developed anti-tumor drug KY-1 at Shandong Cancer Hospital. A 70-year-old patient with cholangiocarcinoma showed a remarkable 73% reduction in the primary tumor lesion after KY-1 treatment, meeting the criteria for partial response (PR) in the first formal tumor evaluation, bringing new hope for the treatment of this refractory cancer.

The patient (subject ID: 01011) was a 70-year-old male diagnosed with highly aggressive cholangiocarcinoma. In the fifth dose group (100mg) of KY-1's clinical trial, medical imaging assessment after two treatment cycles revealed a 73% reduction in the primary tumor lesion, far exceeding the PR evaluation threshold (≥30% tumor shrinkage). Cholangiocarcinoma is notoriously difficult to treat, especially in elderly patients, where existing therapies have limited efficacy. A 73% tumor regression in this case is highly encouraging clinically. This result provides a positive signal for KY-1’s potential in cholangiocarcinoma treatment, particularly its possible efficacy in elderly patients.

KY-1 is an innovative drug independently developed by KeyeLife. The company’s chairman and chief scientist Yandong Zhang stated: "The five-year survival rate for cholangiocarcinoma is less than 10%-30%, and treatment tolerance in elderly patients over 70 poses a significant clinical challenge. The outcome of patient 01011 not only validates KY-1’s anti-tumor potential but also highlights its prospects for elderly patients." Based on these promising results, KeyeLife announced plans to accelerate KY-1’s clinical development, expand trial scale, and further verify its efficacy and safety in cholangiocarcinoma and other potential indications.